Pharvaris N.V.
Pharvaris N.V. (PHVS) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · PHVS · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
33
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Pharvaris N.V. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
PHVS insider buying and selling by quarter
PHVS insider selling · PHVS insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · PHVS ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
PHVS executive sell shares · PHVS board member insider trading · PHVS insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 21, 2026 | Monges Viviane Director | Sale | 9,667 | $293K | Form 4 |
| May 22, 2026 | Nijdam Anna PAO | Option | 5,501 | $110K | Form 4 |
| May 21, 2026 | Nijdam Anna PAO | Option | 1,829 | $37K | Form 4 |
| May 22, 2026 | Nijdam Anna PAO | Sale | 5,501 | $169K | Form 4 |
| May 21, 2026 | Nijdam Anna PAO | Sale | 1,829 | $56K | Form 4 |
| May 21, 2026 | Nassif David W. CFO / CLO | Sale | 10,000 | $303K | Form 4 |
| May 20, 2026 | Bjork Elisabeth Director | Option | 10,000 | $81K | Form 4 |
| May 20, 2026 | Bjork Elisabeth Director | Sale | 10,000 | $293K | Form 4 |
| May 18, 2026 | Modig Berndt CEO · Director | Sale | 2,292 | $67K | Form 4 |
| May 15, 2026 | Glassman Robert Director | Option | 5,333 | $119K | Form 4 |
| May 15, 2026 | Glassman Robert Director | Sale | 5,333 | $159K | Form 4 |
| May 15, 2026 | Glassman Robert Director | Sale | 4,667 | $139K | Form 4 |
| May 15, 2026 | Abele Stefan Andreas Chief Technical Ops Officer | Sale | 8,748 | $261K | Form 4 |
| May 15, 2026 | Souverijns Wim Chief Commercial Officer | Sale | 10,000 | $299K | Form 4 |
| May 11, 2026 | Lu Peng Chief Medical Officer | Other | 109 | $3K | Form 4 |
| May 12, 2026 | Lu Peng Chief Medical Officer | Other | 117 | $4K | Form 4 |
| May 1, 2026 | Lu Peng Chief Medical Officer | Option | 14,166 | $37K | Form 4 |
| May 1, 2026 | Lu Peng Chief Medical Officer | Sale | 14,023 | $423K | Form 4 |
| May 1, 2026 | Lu Peng Chief Medical Officer | Sale | 143 | $4K | Form 4 |
| Apr 29, 2026 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale | 3,830 | $115K | Form 4 |
| Apr 30, 2026 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale | 28,400 | $861K | Form 4 |
| Apr 30, 2026 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale | 670 | $21K | Form 4 |
| Apr 29, 2026 | Lesage Anne Chief Early Development | Sale | 3,700 | $111K | Form 4 |
| Apr 30, 2026 | Lesage Anne Chief Early Development | Sale | 19,200 | $581K | Form 4 |
| Apr 30, 2026 | Lesage Anne Chief Early Development | Option | 18,000 | $145K | Form 4 |
Abele Stefan Andreas
Chief Technical Ops Officer
Date
May 15
Shares
8,748
Price
$29.82
Value
$261K
Souverijns Wim
Chief Commercial Officer
Date
May 15
Shares
10,000
Price
$29.92
Value
$299K
Schikan Johannes Gerardus Christiaan Petrus
Director
Date
Apr 29
Shares
3,830
Price
$30.07
Value
$115K
Schikan Johannes Gerardus Christiaan Petrus
Director
Date
Apr 30
Shares
28,400
Price
$30.30
Value
$861K
Schikan Johannes Gerardus Christiaan Petrus
Director
Date
Apr 30
Shares
670
Price
$31.03
Value
$21K
Lesage Anne
Chief Early Development
Date
Apr 29
Shares
3,700
Price
$30.06
Value
$111K
Lesage Anne
Chief Early Development
Date
Apr 30
Shares
19,200
Price
$30.26
Value
$581K
Lesage Anne
Chief Early Development
Date
Apr 30
Shares
18,000
Price
$8.05
Value
$145K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About PHVS insider trading
PHVS insider trades
Pharvaris N.V. (PHVS) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Lu Peng (Chief Medical Officer), Lesage Anne (Chief Early Development), Nijdam Anna (PAO). Over the past 12 months, 5 insiders have filed transactions with the SEC. PHVS insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Pharvaris N.V.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
PHVS insider trading · 5 questionsThe insiders of Pharvaris N.V. (PHVS) include executives and directors such as Lu Peng (Chief Medical Officer), Lesage Anne (Chief Early Development), Nijdam Anna (PAO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026